charlton_vach
29 Mar 2019
+3% holding His holding has risen @40% so not a bad buy.
Rhino1958
29 Mar 2019
+3% holding Very positive moves yesterday and again today. Mortazevi certainly sees the value that others do not
loper
15 Mar 2019
+3% holding Puzzles me too. The sudden departure of Mortazevi from Silence , the secret negotiation with Alnylam and then the deal with Alnylam and the collapse in the share price of SLN all happened in quick succession. ? Connected. At least Mortazevi has recognised the value in RENE and the ridiculously low price of he shares.
charlton_vach
12 Mar 2019
+3% holding Any thoughts on Ali Mortazavi’s purchases in the past week? He now holds over 3% of RENE shares. He was CEO at Silence Therapeutics but left suddenly last year, any ideas why? I notice the share price there is only 35% of what it was when he left and at an all time low.
Rhino1958
04 Mar 2019
25% increase today Long may it continue hopefully further good news on its way
mol42
22 Feb 2019
Good News and a bit of coverage today Pharmaphorum – 22 Feb 19 Cell therapy produces encouraging first results in eye trial - Pharmaphorum UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa. below for those who are wary of clicking links February 22, 2019 UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP). The only results so far are from three subjects in the first cohort in phase 2 of a phase 1/2 trial of the disease. But this therapy is based on a dose of human retinal progenitor cells, and if approved could be a competitor to Spark/Novartis’s Luxturna (voretigene neparvovec). Unlike the already-approved gene therapy Luxturna, ReNeuron’s cell-based therapy would not be limited to patients with a disease caused by a certain mutation. Luxturna is based around a virus delivering genetic material to correct a genetic sight defect, while ReNeuron’s therapy involves human retinal progenitor cells (hRPC) being embedded in the back of the eye. This creates new photo receptors – and represents the first time new photo receptors have ever been created in humans. ReNeuron said all three subjects in the first cohort of the phase 2 part of the trial have demonstrated a significant improvement in vision at follow-up compared with their pre-treatment baseline and compared with the untreated eye. At most recent follow-up, at two months follow-up for one subject, and at 18 days for the other two, subjects showed average improvement equivalent to reading an additional three lines of five letters on a standard eye chart. The first patient could see only nine letters at baseline, but this had improved to 29 letters after a two-month follow up. A second patient improved from nine letters to 24 after 18 days, and the third improved from 32 letters to 46 after 18 days. The phase 2 part of the phase 1/2 trial uses a cryopreserved, commercially ready hRPC formulation, and enrols subjects with some retinal functionality. ReNeuron noted that these are early data and it will continue with the trial to monitor the three treated patients, and assess whether the effects are maintained over a long period of time. The phase 1/2 study is being conducted at two clinical sites in the US – Massachusetts Eye and Ear in Boston and Retinal Research Institute in Phoenix, Arizona – and is an open-label study to evaluate the safety, tolerability and preliminary efficacy of the hRPC stem cell therapy candidate in patients with advanced RP. RP is a group of hereditary diseases of the eye that leads to progressive loss of sight due to cells in the retina becoming damaged and eventually dying. Dosing in the phase 1 part of the study was completed last year in 12 subjects with extensive retinal damage and very limited remaining vision to establish the safety of the treatment. The safety and visual stability data from this part of the study resulted in the Data Safety Monitoring Board (DSMB) approving the transition to a commercially ready hRPC drug product formulation to be administered to patients with less retinal damage and consequently better visual potential. Dosing of the second cohort of three phase 2 subjects is expected to commence in March following DSMB review of the clinical data from the first phase 2 cohort. Based on the positive early data thus far from the phase 1/2 study, ReNeuron will consult with regulators for advice on further clinical development. The FDA has already granted it a Fast Track development process, with greater support during clinical development, and potentially a faster six-month review of data once trials are complete. will consider increasing my holding (albeit very reduced) over the weekend bw all mol
mol42
22 Feb 2019
Edison update 220219 btw the number of events at which we are attending has been updated again eg OH in zurich Monday [link] mol
mol42
22 Feb 2019
Edison update 220219 edisoninvestmentresearch.com Exciting positive data in retinitis pigmentosa (RP) | ReNeuron Group ReNeuron Group - Exciting positive data in retinitis pigmentosa (RP) mol
omg
22 Feb 2019
Good News Hi Vach I know what you mean but can not help thinking we missed a trick when the guy with the stem cells starting playing the piano after treatment. I know it is not the ‘British’ way but this could and should have been a big news story. So many companies have promoted just theories to a massive amount and we had living proof. Anyway it is what it is Omg
mol42
21 Feb 2019
Bit of info just thought i’d post on this thread as well as relevant to thread good news indeed mol
mol42
21 Feb 2019
Good News Interview mol
charlton_vach
20 Feb 2019
Good News I think we would have omg if the testing phases in this country weren’t so laborious
omg
20 Feb 2019
Good News Pity we haven’t had more news like this over the years and years… omg
mol42
18 Feb 2019
Bit of info BBC News Gene therapy first to 'halt' blindness A woman from Oxford has been treated with gene therapy in a world first, in a bid to stop sight loss. And re Coffey BBC News 'I've been given my sight back' Two patients have had pioneering stem cell therapy to restore their vision. Albeit not the disease of the eye we are pursuing And in clinical trials with - haven’t though checked re us and Jcyte recently Another v disappointing day re sp Mind unfortunately we should be used to that over the years and especially consolidation mol
mol42
13 Feb 2019
OT, for mol you just be what you are ym a superstar amongst homo sapiens in the grand scheme of life - (there isn’t any - lol) mvbwae it’s what we used to do - i agree fun times and definitely a joy to talk with you over the years but this site now is not conducive to same mind supposed to be a share discussion board afterall lol mol
